Finanzen von QuidelOrtho Corp (QDEL)QDELQuidelOrtho Corp

QuidelOrtho Corp (QDEL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Labs, accounting for 60.7% of total sales, equivalent to $382.90M. Other significant revenue streams include Immunohematology and Point-of-Care. Understanding this composition is critical for investors evaluating how QDEL navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, QuidelOrtho Corp maintains a gross margin of 35.25%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2.58%, while the net margin is -14.72%. These profitability ratios, combined with a Return on Equity (ROE) of -45.91%, provide a clear picture of how effectively QDEL converts its operational activities into shareholder value.

In the context of the broader market, QDEL competes directly with industry leaders such as SIBN and BBNX. With a market capitalization of $974.46M, it holds a leading position in the sector. When comparing efficiency, QDEL's gross margin of 35.25% stands against SIBN's 79.54% and BBNX's 59.04%. Such benchmarking helps identify whether QuidelOrtho Corp is trading at a premium or discount relative to its financial performance.

QuidelOrtho has been struggling financially, with a net income of -$733 million in Q3 2025 and a gross margin of 35.25% in Q2 2026, indicating ongoing challenges in profitability. However, the revenue for Q4 2024 is projected at $707.8 million, showing potential for recovery.